Surface Oncology Inc (NASDAQ:SURF)

3.64
Delayed Data
As of Jan 26
 -0.20 / -5.21%
Today’s Change
3.52
Today|||52-Week Range
12.98
-23.85%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$171.6M

Company Description

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm's pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also include licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.

Contact Information

Surface Oncology, Inc.
50 Hampshire Street
Cambridge Massachusetts 02139
P:(617) 714-4096
Investor Relations:

Employees

Shareholders

Individual stakeholders35.82%
Mutual fund holders29.76%
Other institutional13.80%

Top Executives

Robert W. RossPresident, Chief Executive Officer & Director
Jessica FeesChief Financial Officer
Vito J. PalombellaChief Scientific Officer
Alison M. O'NeillChief Medical Officer
Shannon Rourke DevensSenior Vice President-Development Operation